Roche News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

11.10.23	Genentech's Ocrevus Effectively Manages MS Disease Activity In Black And Hispanic / Latinx People (RTTNews)
10.10.23	Genentech's Vabysmo Maintains Vision Improvements In Phase III Trials - Quick Facts (RTTNews)
04.10.23	Genentech: Majority Of Newborn Babies With SMA Treated With Evrysdi Able To Sit After 1 Yr Treatment (RTTNews)
20.09.23	PeptiDream Collaborates With Genentech For Discovery And Development Of Peptide-RI Drug Conjugates (RTTNews)
06.09.23	Genentech : FDA Accepts BLA For Crovalimab For Treatment Of Rare Life-Threatening Blood Condition (RTTNews)
05.09.23	Nykode Stock Up As FDA Approves IND For VB-C-04 Trial Of VB10.16 In HPV16-Positive Cervical Cancer (RTTNews)
05.09.23	Economist Impact report, Advancing the frontier of health and technology integration: The 2023 Digital Health Barometer highlights opportunities in digitalisation of healthcare (PR Newswire)
01.09.23	Genentech : Phase III Study Of Alecensa In ALK-Positive Early-Stage Lung Cancer Meets Main Goal (RTTNews)
31.08.23	Biotech Stocks Facing FDA Decision In September 2023 (RTTNews)
29.08.23	Roche' Tecentriq Subcutaneous Approved In Great Britain For All Indications Of Intravenous Tecentriq (RTTNews)
29.08.23	EU Okays Roche's Evrysdi For Babies Under Two Months Old With Spinal Muscular Atrophy (RTTNews)
23.08.23	Roche's Unintentional Data Leak Unveils Positive Prospects For Lung Cancer Treatment (RTTNews)
23.08.23	Genentech Issues Update On Phase III SKYSCRAPER-01 Study - Quick Facts (RTTNews)
17.08.23	Roche launches a new addition to the cobas® connection modules, the CCM Vertical, helping to improve laboratory efficiency (PR Newswire)
08.08.23	New opportunities and persistent challenges revealed as organisations attempt more data-driven approaches to healthcare, says new report from Harvard Business Review Analytic Services (PR Newswire)
03.08.23	Roche Says It Expands Global Business Partnership Agreement With Sysmex (RTTNews)
03.08.23	Roche expands long-term alliance with Sysmex (PR Newswire)
27.07.23	Roche H1 Core Operating Profit Declines On Lower Demand For COVID-19 Products; Confirms 2023 Outlook (RTTNews)
19.07.23	Roche to showcase next-generation diagnostic solutions at the American Association of Clinical Chemistry 2023 Clinical Lab Expo (PR Newswire)
14.07.23	Roivant Sciences In Talks To Sell Stomach Drug To Roche In More Than $7 Bln Deal : Report (RTTNews)
13.07.23	Genentech : Phase III Trial Of Ocrevus In Multiple Sclerosis Meets Primary And Secondary Endpoints (RTTNews)
11.07.23	Roche Says Columvi Gets EC Approval To Treat R/R Diffuse Large B-cell Lymphoma (RTTNews)
27.06.23	Roche Says FDA Clears Additional Alzheimer's Disease Cerebrospinal Fluid Assays (RTTNews)
27.06.23	Roche receives FDA clearance for additional Alzheimer's disease Cerebrospinal Fluid (CSF) assays, supporting timely diagnosis and treatment decision-making (PR Newswire)
16.06.23	FDA Oks Roche's Columvi To Treat Adult With Relapsed Or Refractory Diffuse Large B-cell Lymphoma (RTTNews)
13.06.23	Roche Granted WHO Prequalification For The Cobas HPV Test (RTTNews)
17.05.23	Genentech Reports Positive Trial Results For Fenebrutinib In Relapsing Forms Of Multiple Sclerosis (RTTNews)
17.05.23	Roche showcases commitment to advancing innovative diagnostic solutions at WorldLab-EuroMedLab (PR Newswire)
09.05.23	FDA Accepts SBLA For Genentech's Vabysmo For Retinal Vein Occlusion Treatment (RTTNews)
08.05.23	SD Biosensor Recalls Certain COVID-19 At-Home Tests Distributed By Roche (RTTNews)
26.04.23	Roche Q1 Group Sales Down 3% At CER; Confirms 2023 Outlook (RTTNews)
17.04.23	Genentech : Tecentriq Combination Reduces Risk Of Cancer Returning In People With Liver Cancer (RTTNews)
13.04.23	Genentech : Vabysmo Data Suggest Rapid Drying Of Retinal Fluid In Patients With Wet AMD And DME (RTTNews)
11.04.23	Roche Introduces Digital Library Of Medical Algorithms 'navify Algorithm Suite' (RTTNews)
11.04.23	Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care (PR Newswire)
31.03.23	Biotech Stocks Facing FDA Decision In April 2023 (RTTNews)
30.03.23	Omega Enters Supply Agreement With Roche To Evaluate OTX-2002 In Combination With Atezolizumab (RTTNews)
29.03.23	Astellas, Roche To Develop Integrated Diabetes Self-management Solution With BlueStar (RTTNews)
22.03.23	Roche, Lilly To Develop Elecsys Amyloid Plasma Panel To Boost Early Diagnosis Of Alzheimer's Disease (RTTNews)
20.03.23	Roche : New Data For Evrysdi Reinforce Long-Term Efficacy And Safety Profile In Types 2 And 3 SMA (RTTNews)
10.03.23	FDA Panel Backs Genentech' Polivy Combination For Untreated Diffuse Large B-Cell Lymphoma (RTTNews)
06.03.23	Roche Announces FDA Approval Of Label Expansion For VENTANA PD-L1 Assay (RTTNews)
06.03.23	Roche receives FDA approval of label expansion for VENTANA PD-L1 (SP263) Assay to identify patients with locally advanced and metastatic non-small cell lung cancer eligible for Libtayo (PR Newswire)
28.02.23	Biotech Stocks Facing FDA Decision In March 2023 (RTTNews)
28.02.23	Roche Collaborates With CDC To Strengthen Laboratory Capabilities In Countries Affected By HIV & TB (RTTNews)
28.02.23	Roche joins forces with the U.S. Centers for Disease Control and Prevention to strengthen laboratory systems in the fight against the HIV and tuberculosis epidemics (PR Newswire)
10.02.23	Genentech : Phase III Data Show Vabysmo Improves Vision And Reduced Retinal Fluid In RVO (RTTNews)
09.02.23	Roche expands collaboration with Janssen to advance personalised healthcare through companion diagnostics (PR Newswire)
07.02.23	Roche Announces Positive Results From Phase III Study Of Crovalimab In PNH (RTTNews)
01.02.23	EC Approves Label Expansion Of Roche' Hemlibra To Include People With Moderate Haemophilia A (RTTNews)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

25.06.24		Roche kann EU-Zulassung für Multiple-Sklerose-Mittel an Land ziehen - Aktie sinkt dennoch
10.06.24		Roche-Aktie dennoch tiefer: EU-Kommission lässt Lungenkrebsmedikament Alecensa zu
21.05.24		Roche-Aktie schwächer: Roche-Übernahme von LumiraDx in prüfung - Inavolisib erhält "Breakthrough Therapy"-Status
11.12.23		Roche-Aktie etwas fester: Roche legt Studiendaten zu Kadcyla, Hemlibra, Columvi und Lunsumio vor
02.02.23		Roche-Aktie schwächer: Roche erreicht 2022 Prognose - Umsatz- und Gewinnrückgang im neuen Jahr erwartet
27.12.22		Roche-Aktie leichter: FDA lässt Roches Lymphom-Behandlung Lunsumio zu
16.09.22		Roche-Aktie gewinnt: Moody's hebt Bonitätseinstufung für Roche an
25.04.22		Roche-Aktie leichter: Umsatz übertrifft Erwartungen

25.06.24

Roche kann EU-Zulassung für Multiple-Sklerose-Mittel an Land ziehen - Aktie sinkt dennoch

10.06.24

Roche-Aktie dennoch tiefer: EU-Kommission lässt Lungenkrebsmedikament Alecensa zu

21.05.24

Roche-Aktie schwächer: Roche-Übernahme von LumiraDx in prüfung - Inavolisib erhält "Breakthrough Therapy"-Status

11.12.23

Roche-Aktie etwas fester: Roche legt Studiendaten zu Kadcyla, Hemlibra, Columvi und Lunsumio vor

02.02.23

Roche-Aktie schwächer: Roche erreicht 2022 Prognose - Umsatz- und Gewinnrückgang im neuen Jahr erwartet

27.12.22

Roche-Aktie leichter: FDA lässt Roches Lymphom-Behandlung Lunsumio zu